Constitutional fever (low-grade / FUO-like)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-12 — Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study.: 2026 — MFSAF v4.0 validation in MF confirmed the fever item as content-valid and reliable within the instrument’s constitutional-symptom domain, with 1–2-point item change judged meaningful — supporting standardized capture of low-grade constitutional fever in MF endpoints. (novelty: 3)
Open questions
Related
Contributing findings
How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?
23-oct-2026
novelty 2
per-area 1
mentions
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
13-aug-2026
novelty 2
per-area 1
mentions
Patient-reported outcomes of symptom burden and quality of life in patients with polycythemia vera and essential thrombocythemia in Korea: A cross-sectional study.
01-aug-2026
novelty 2
per-area 2
strengthens
Case Report: Polycythemia vera presenting as persistent unexplained low-grade fever.
24-jul-2026
novelty 2
per-area 2
introduces
SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis.
23-jul-2026
novelty 2
per-area 1
mentions
Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation.
13-jul-2026
novelty 2
per-area 1
mentions
Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.
21-jun-2026
novelty 2
per-area 1
mentions
Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study.
12-jun-2026
novelty 3
per-area 2
mentions